Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Caris Life Sciences Inc’s stock clocked out at $25.0, down -2.15% from its previous closing price of $25.55. In other words, the price has decreased by -$2.15 from its previous closing price. On the day, 1.67 million shares were traded. CAI stock price reached its highest trading level at $25.69 during the session, while it also had its lowest trading level at $24.74.
Ratios:
To gain a deeper understanding of CAI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.36 and its Current Ratio is at 9.93. In the meantime, Its Debt-to-Equity ratio is 0.89 whereas as Long-Term Debt/Eq ratio is at 0.88.
Upgrades & Downgrades
In the most recent recommendation for this company, Canaccord Genuity on December 02, 2025, initiated with a Hold rating and assigned the stock a target price of $28.
On July 14, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $32.
On July 14, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $32.TD Cowen initiated its Buy rating on July 14, 2025, with a $32 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 11 ’25 when Power Luke Thomas sold 62,250 shares for $26.58 per share. The transaction valued at 1,654,461 led to the insider holds 99,571 shares of the business.
LUKE POWER bought 62,250 shares of CAI for $1,686,975 on Dec 11 ’25. On Nov 07 ’25, another insider, Denton John Russel, who serves as the insider of the company, bought 4,184 shares for $24.09 each. As a result, the insider paid 100,793 and bolstered with 9,184 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CAI now has a Market Capitalization of 7053672960 and an Enterprise Value of 6724918272. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.87 while its Price-to-Book (P/B) ratio in mrq is 14.74. Its current Enterprise Value per Revenue stands at 10.361 whereas that against EBITDA is -126.995.
Stock Price History:
Over the past 52 weeks, CAI has reached a high of $42.50, while it has fallen to a 52-week low of $22.86. The 50-Day Moving Average of the stock is -5.72%, while the 200-Day Moving Average is calculated to be -15.38%.
Shares Statistics:
It appears that CAI traded 2.12M shares on average per day over the past three months and 2591390 shares per day over the past ten days. A total of 282.10M shares are outstanding, with a floating share count of 115.26M. Insiders hold about 59.13% of the company’s shares, while institutions hold 37.59% stake in the company. Shares short for CAI as of 1767139200 were 6203433 with a Short Ratio of 2.93, compared to 1764288000 on 6840155. Therefore, it implies a Short% of Shares Outstanding of 6203433 and a Short% of Float of 4.2600001999999995.
Earnings Estimates
. The current assessment of Caris Life Sciences Inc (CAI) involves the perspectives of 3 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.04 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.66 and -$0.73 for the fiscal current year, implying an average EPS of -$0.69. EPS for the following year is $0.18, with 4.0 analysts recommending between $0.46 and -$0.05.
Revenue Estimates
For the next quarter, 1 analysts are estimating revenue of $205.3M. There is a high estimate of $214M for the next quarter, whereas the lowest estimate is $200.7M. Based on 9 analysts’ estimates, the company’s revenue will be $980.41M in the next fiscal year. The high estimate is $1.02B and the low estimate is $941M.
